Raab & Moskowitz Asset Management LLC Sells 39,910 Shares of Pfizer Inc. $PFE

Raab & Moskowitz Asset Management LLC decreased its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 14.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 240,964 shares of the biopharmaceutical company’s stock after selling 39,910 shares during the period. Pfizer makes up about 1.3% of Raab & Moskowitz Asset Management LLC’s holdings, making the stock its 19th biggest holding. Raab & Moskowitz Asset Management LLC’s holdings in Pfizer were worth $6,000,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp lifted its stake in Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after purchasing an additional 2,786,098 shares during the last quarter. Northern Trust Corp grew its stake in shares of Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after buying an additional 869,175 shares during the last quarter. Fisher Asset Management LLC grew its stake in shares of Pfizer by 1.9% during the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after buying an additional 897,786 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Pfizer by 8.6% in the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after buying an additional 3,296,415 shares during the period. Finally, Amundi increased its holdings in shares of Pfizer by 10.8% in the third quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock worth $1,096,380,000 after buying an additional 4,043,413 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PFE. BMO Capital Markets restated an “outperform” rating and set a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, February 4th. HSBC boosted their price objective on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. TD Cowen reissued a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Finally, Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $28.19.

Read Our Latest Analysis on PFE

Pfizer Stock Up 0.2%

NYSE PFE opened at $28.37 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $28.75. The stock has a market capitalization of $161.29 billion, a PE ratio of 20.86 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The business’s 50-day moving average is $27.09 and its 200 day moving average is $25.82.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.63 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

See Also

• Five stocks we like better than Pfizer

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).